dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Perez, Ariel |
dc.contributor.author | Iacoboni García-Calvo, Gloria |
dc.contributor.author | Penack, Olaf |
dc.contributor.author | Jentzsch, Liv |
dc.contributor.author | Carpio Segura, Cecilia Carmen |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Rejeski, Kai |
dc.contributor.author | Bücklein, Veit |
dc.date.accessioned | 2022-09-06T12:22:15Z |
dc.date.available | 2022-09-06T12:22:15Z |
dc.date.issued | 2022-05 |
dc.identifier.citation | Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May;10(5):e004475. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/8036 |
dc.description | Neoplasias hematológicas; Receptores; Antígeno quimérico |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;10(5) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Cèl·lules B - Tumors - Tractament |
dc.subject | Immunoteràpia |
dc.subject | Antígens CD - Immunologia |
dc.subject.mesh | Lymphoma, Large B-Cell, Diffuse |
dc.subject.mesh | /therapy |
dc.subject.mesh | Immunotherapy, Adoptive |
dc.subject.mesh | Antigens, CD19 |
dc.title | The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2021-004475 |
dc.subject.decs | linfoma de células B grandes difuso |
dc.subject.decs | /terapia |
dc.subject.decs | inmunoterapia adoptiva |
dc.subject.decs | antígenos CD19 |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2021-004475 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Rejeski K] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany. [Perez A] Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA. [Iacoboni G, Carpio C, Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. [Penack O] Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. German Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany. [Bücklein V] Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. [Jentzsch L] Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany |
dc.identifier.pmid | 35580927 |
dc.identifier.wos | 000797594100008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |